MicroRNAs as potential therapeutic targets in kidney disease

Journal of the Formosan Medical Association

Volumn 112, Issue 5, 2013, Pages 237-243

  Gomez, Ivan G ^a,b,c   Grafals, Monica ^d,e   Portilla, Didier ^f   Duffield, Jeremy S ^a,b,c  

^a Division of Nephrology   (United States)

^b Center for Lung Biology   (United States)

^c Institute for Stem Cells and Regenerative Medicine   (United States)

^d LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^e TUFTS UNIVERSITY   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Chronic allograft disease; Chronic kidney disease; Kidney fibrosis; Peroxisome proliferator activated receptor; Reactive oxygen species

Indexed keywords

ADENOSINE TRIPHOSPHATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GENTAMICIN; GLITAZONE DERIVATIVE; LET 7C; MESSENGER RNA; MICRORNA; MICRORNA 10A; MICRORNA 10B; MICRORNA 125A; MICRORNA 200A; MICRORNA 21; MICRORNA 21 ANTIBODY; MICRORNA 30A; MICRORNA 30B; MICRORNA 30C; MICRORNA 30E; MICRORNA 32; OLIGONUCLEOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; SMALL UNTRANSLATED RNA; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLOOD CHEMISTRY; CELL CYCLE ARREST; CHRONIC ALLOGRAFT DYSFUNCTION; CHRONIC KIDNEY DISEASE; CIRCULATION; CYTOPLASM; DIABETIC NEPHROPATHY; DISEASE COURSE; ENDOPLASMIC RETICULUM STRESS; EXOSOME; FIBROBLAST; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; KIDNEY INJURY; MOLECULARLY TARGETED THERAPY; MYOFIBROBLAST; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OLIGONUCLEOTIDE THERAPY; PATHOGENESIS; PROTEIN LOCALIZATION; PROTEIN MICROARRAY; RENAL GRAFT DYSFUNCTION; REVIEW; URINALYSIS; URINE;

ANIMALS; EPITHELIAL CELLS; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; KIDNEY DISEASES; MICRORNAS;

EID: 84877627124     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/j.jfma.2012.12.011     Document Type: Review

References (40)

1. Snyder J.J., Foley R.N., Collins A.J. Prevalence of CKD in the United States: a sensitivity analysis using the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis 2009, 53:218-228.
2. Zhang L., Zhang P., Wang F., Zuo L., Zhou Y., Shi Y., et al. Prevalence and factors associated with CKD: a population study from Beijing. Am J Kidney Dis 2008, 51:373-384.
3. Imai E., Horio M., Iseki K., Yamagata K., Watanabe T., Hara S., et al. Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 2007, 11:156-163.
4. Johnson R.J., Herrera-Acosta J., Schreiner G.F., Rodriguez-Iturbe B. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002, 346:913-923.
5. Ishii Y., Sawada T., Kubota K., Fuchinoue S., Teraoka S., Shimizu A. Injury and progressive loss of peritubular capillaries in the development of chronic allograft nephropathy. Kidney Int 2005, 67:321-332.
6. Schrimpf C., Duffield J.S. Mechanisms of fibrosis: the role of the pericyte. Curr Opin Nephrol Hypertens 2011, 20:297-305.
7. Ishani A., Xue J.L., Himmelfarb J., Eggers P.W., Kimmel P.L., Molitoris B.A., et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol 2009, 20:223-228.
8. Lee R., Feinbaum R., Ambros V. A short history of a short RNA. Cell 2004, 116:S89-S92.
9. Dugas D.V., Bartel B. MicroRNA regulation of gene expression in plants. Curr Opin Plant Biol 2004, 7:512-520.
10. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
11. Chau B.N., Xin C., Hartner J., Ren S., Castano A.P., Linn G., et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med 2012, 4:121ra18.
12. Melo S.A., Esteller M. Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett 2011, 585:2087-2099.
13. Medina P.P., Nolde M., Slack F.J. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010, 467:86-90.
14. Gao P., Tchernyshyov I., Chang T.-C., Lee Y.-S., Kita K., Ochi T., et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009, 458:762-765.
15. Cheng Y., Ji R., Yue J., Yang J., Liu X., Chen H., et al. MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy?. Am J Pathol 2007, 170:1831-1840.
16. Humphreys B.D., Lin S.-L., Kobayashi A., Hudson T.E., Nowlin B.T., Bonventre J.V., et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol 2010, 176:85-97.
17. Lin S.-L., Kisseleva T., Brenner D.A., Duffield J.S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008, 173:1617-1627.
18. Asada N., Takase M., Nakamura J., Oguchi A., Asada M., Suzuki N., et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 2011, 121:3981-3990.
19. Chang F.-C., Chou Y.-H., Chen Y.-T., Lin S.-L. Novel insights into pericyte-myofibroblast transition and therapeutic targets in renal fibrosis. J Formos Med Assoc 2012, XX:1-10.
20. Friedman S.L., Sheppard D., Duffield J.S., Violette S. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med 2013 Jan 9, 5(167):167sr1. 10.1126/scitranslmed.3004700.
21. Godwin J.G., Ge X., Stephan K., Jurisch A., Tullius S.G., Iacomini J. Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl Acad Sci U S A 2010, 107:14339-14344.
22. Zarjou A., Yang S., Abraham E., Agarwal A., Liu G. Identification of a microRNA signature in renal fibrosis: role of miR-21. Am J Physiol Renal Physiol 2011, 301:F793-F801.
23. Anglicheau D., Sharma V.K., Ding R., Hummel A., Snopkowski C., Dadhania D., et al. MicroRNA expression profiles predictive of human renal allograft status. Proc Natl Acad Sci U S A 2009, 106:5330-5335.
24. Putta S., Lanting L., Sun G., Lawson G., Kato M., Natarajan R. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol 2012, 23:458-469.
25. Qin W., Chung A.C.K., Huang X.R., Meng X.-M., Hui D.S., Yu C.-M., et al. TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 2011, 22:1462-1474.
26. Volinia S., Visone R., Galasso M., Rossi E., Croce C.M. Identification of microRNA activity by Targets' Reverse EXpression. Bioinformatics 2010, 26:91-97.
27. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
28. Zampetaki A., Willeit P., Drozdov I., Kiechl S., Mayr M. Profiling of circulating microRNAs: from single biomarkers to re-wired networks. Cardiovasc Res 2012, 93:555-562.
29. Saikumar J., Hoffmann D., Kim T.-M., Gonzalez V.R., Zhang Q., Goering P.L., et al. Expression, circulation, and excretion profile of microRNA-21, -155, and -18a following acute kidney injury. Toxicol Sci 2012, 129:256-267.
30. Patrick D.M., Montgomery R.L., Qi X., Obad S., Kauppinen S., Hill J.A., et al. Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. J Clin Invest 2010, 120:3912-3916.
31. Li S., Nagothu K.K., Desai V., Lee T., Branham W., Moland C., et al. Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-alpha in mice confers protection during acute kidney injury. Kidney Int 2009, 76:1049-1062.
32. Li S., Basnakian A., Bhatt R., Megyesi J., Gokden N., Shah S.V., et al. PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. Am J Physiol Renal Physiol 2004, 287:F990-F998.
33. Krick S., Shi S., Ju W., Faul C., Tsai S.-Y., Mundel P., et al. Mpv17l protects against mitochondrial oxidative stress and apoptosis by activation of Omi/HtrA2 protease. Proc Natl Acad Sci U S A 2008, 105:14106-14111.
34. Kashihara N., Haruna Y., Kondeti V.K., Kanwar Y.S. Oxidative stress in diabetic nephropathy. Curr Med Chem 2010, 17:4256-4269.
35. Modlinger P.S., Wilcox C.S., Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol 2004, 24:354-365.
36. O'Bryan T., Weiher H., Rennke H.G., Kren S., Hostetter T.H. Course of renal injury in the Mpv17-deficient transgenic mouse. J Am Soc Nephrol 2000, 11:1067-1074.
37. Clozel M., Hess P., Fischli W., Löffler B.M., Zwacka R.M., Reuter A., et al. Age-dependent hypertension in Mpv17-deficient mice, a transgenic model of glomerulosclerosis and inner ear disease. Exp Gerontol 1999, 34:1007-1015.
38. Schenkel J., Zwacka R.M., Rutenberg C., Reuter A., Waldherr R., Weiher H. Functional rescue of the glomerulosclerosis phenotype in Mpv17 mice by transgenesis with the human Mpv17 homologue. Kidney Int 1995, 48:80-84.
39. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
40. Burgess H.A., Daugherty L.E., Thatcher T.H., Lakatos H.F., Ray D.M., Redonnet M., et al. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005, 288:L1146-L1153.